In Vitro Diagnostics market seen reaching $189.72 billion by 2035

Market Research Future forecasts the global in vitro diagnostics market will rise from $110.94 billion in 2026 to $189.72 billion by 2035, driven by chronic disease growth, point-of-care testing and AI-enabled laboratory automation. The outlook points to steady demand across hospitals, clinics and decentralized testing sites as health systems expand diagnostic capacity.

Why it matters: - The in vitro diagnostics market is tied to recurring clinical demand, not one-time purchases, which makes it a core part of chronic disease care. - Faster testing and more decentralized diagnostics can shorten treatment delays, expand access in rural and community settings, and ease pressure on centralized laboratories. - AI automation is changing lab economics by cutting manual steps and improving turnaround times.

What happened: - Market Research Future said the global in vitro diagnostics market will grow from $110.94 billion in 2026 to $189.72 billion by 2035. - The forecast implies a 6.72% compound annual growth rate from 2026 through 2035. - The market was estimated at $104.18 billion in 2025. - The forecast is driven by rising chronic disease prevalence, expansion of point-of-care diagnostic devices and AI-driven laboratory automation. - The company also published sample, customization and report links for the study: Request a free sample, Ask for customization and Read detailed insights.

The details: - The International Diabetes Federation projects 643 million adults will live with diabetes by 2030, up from 537 million in 2021. - The WHO Global Cancer Observatory estimates combined breast, prostate and lung cancer diagnoses will surpass 8.5 million annually by 2030. - Chronic diseases account for more than 70% of healthcare spending in OECD countries. - National procurement programs are pushing testing away from centralized labs and into community care settings. - India’s Ayushman Bharat program has driven procurement of more than 150,000 point-of-care diagnostic devices across 160,000 health and wellness centers since 2023. - Major health systems in the US and EU have invested more than $4.5 billion in laboratory consolidation initiatives that combine reagent rental contracts with decision-support software. - The report says AI-enabled automation has replaced legacy manual analyzers with integrated lines that shorten turnaround times by up to 35%. - Cleveland Clinic’s 2024 deployment of a fully automated core laboratory line cut manual handling steps by 42% and improved sample-to-result time by 28%. - CMS’s 2024 decision to extend PAMA reporting cycles and stabilize clinical laboratory fee schedule rates added reimbursement certainty for molecular panels and automated testing platforms. - The global laboratory automation segment drew $2.1 billion in venture and strategic investment during 2023-2024.

Between the lines: - Reagents and kits remain the biggest revenue engine because every analyzer sold creates ongoing consumable demand. - Software and services are growing fastest as labs move toward subscription-based informatics, quality monitoring and regulatory reporting tools. - Immunoassay remains the dominant technology, while molecular diagnostics is expanding fastest on the back of PCR testing and companion diagnostics. - The market is shifting from isolated instruments to connected diagnostic networks that link testing, software and treatment decisions. - Competitive pressure appears to be moving toward integrated service bundles rather than standalone hardware sales.

What's next: - By 2030, Market Research Future expects 60% of high-volume clinical laboratories in OECD countries to use machine-learning tools for pre-analytical screening, result validation and auto-verification. - Precision diagnostics and companion testing are expected to become more central to disease management through the late 2020s. - The FDA’s 2024 framework for phased oversight of laboratory-developed tests is expected to require clinical validity data for high-risk assays by 2028. - Start-ups have raised more than $800 million in venture funding for oncology decision-support tools since 2023. - Regionally, Asia-Pacific is projected to be the fastest-growing market, led by China, India and ASEAN adoption of diagnostic infrastructure. - North America remains the largest market, supported by reimbursement depth and broad automation adoption.

The bottom line: - The diagnostics market’s next growth phase is being driven by chronic disease, decentralized testing and automation, with software and molecular tools capturing more of the value chain.